The employment of the stable isotope labeling with amino acids in cell culture (SILAC) based proteomic analysis as a guidance tool for investigation of cellular response of a multifunctional nanodelivery system has been described for cancer therapy. The multifunctional nanodelivery system in this study was based on an estrogen anchored multimodal nanomicelle (NPG). The key components of the multifunctional nanomicelle consist: β-cyclodextrin conjugated estrone (CDE1), an escort molecule; polymeric BH3 mimetic, a proapoptotic BcL-2 inhibitor; and the mitotic catastrophe agent paclitaxel. They were assembled into the nanomicelle by multiple weak interactions including hydrophobic/hydrophilic interaction and host-guest recognition. The resulting nanomicelle exhibited unimodal morphology with average size of 170 nm with sustained release. It was found that the nanoparticle exhibits excellent anti-tumor activities for the treatment of breast adenocarcinoma with exceptional targeting efficacy both in MCF-7 tumor bearing mice. NPG as a new drug delivery system demonstrated several merits such as the increased drug uptake in breast tumor tissue, low toxicity, potent tumor growth retardation and metastasis inhibition, as well as potential clinical practicality without compromising liver, kidney and immune function and ameliorating the conventional chemotherapeutics induced phlebitis in breast tumor bearing nude mice model. The systematic SILAC based proteomics study and the subsequent validation revealed that the synergistic induction of mitotic catastrophe through enhanced G2/M phase arrest and PI3K/Akt/mTOR mediated autophagy, account for the exceedingly potent anti-tumor activity of this convergent nanomicelle. Additionally, the verification of the top upregulated gene from the proteomics profiling revealed that the overexpression of zinc finger protein 350 (ZNF350/ZBRK1) is associated with the enhanced antitumor effect induced by NPG.
INTRODUCTION
The heterogeneity and instability of cancer genomes results in highly variable clinical outcomes for cancer treatment. 1 In current clinical practice, combination regimens are routinely applied although the scientific evidence for the combination therapies is weak. In a hope of improving the clinical outcome of the combination regimens, combined modality therapy in a nanoformulation in terms of multifunctional nanomedicine has attracted increasing attention and provides a promising direction for cancer therapy. 2 Multifunctional nanomedicines integrate comprehensive functionalities with different mechanisms of drug action, providing targeted, ratiometric delivery of drugs or genes, consequently making significant improvement of their pharmacokinetic/dynamic profile compared to the conventional nanomedicines. [3] [4] [5] [6] However, application of the majority of multifunctional nanodelivery systems are substantially hampered due to their inherent complexity in vivo, including the heterogeneities of tumor vascular permeability, 7 varying pharmacokinetics, nonspecific biodistributions, and unpredicted adverse effects. One critical reason for the limitations is the lack of understanding of the sophisticated drug actions amongst the multiple constituents in the integrated nanoparticles for the treatment of cancer.
Figure 1:
Schematic of the novel nanoparticle. Above is a schematic representation of nanoparticles developed in this study. Targeted multifunctional Nanoparticles formulated by functionalized PEG-PLA and synergetic chemotherapeutics, for improved anticancer activity. The various modifications to the PEG-PLA polymer allow the nanoparticle to be capable of targeted co-delivery of therapeutics. (PEG-PLA: copolymers of polyethylene glycol and polylactic acid; CD: cyclodextrin; AD: Adamantyl group) Previous approaches for assessing drug synergy in multifunctional nanoparticles were usually empirical which always suffered from the low accuracy and uncertain predictability. 6 No doubt, the accurate information of proteome wide cellular response triggered by the multifunctional nanoparticle from proteomics would provide a key to understanding the molecular mechanism underlying the anti-tumor effects from the multiagents interactions in the highly convergent nanoparticles, and consequently facilitate the development of new generation nanotherapeutics for cancer. Proteomics reveals large-scale information of proteomes and uncovers important points in the cell signaling from complex mixtures; and they have attracted increasing attention in drug discovery. [8] [9] SILAC based proteomics, which relies on the incorporation of amino acids with substituted stable isotopic nuclei and enables data interpretation and quantification more accurate and robust, has emerged as a powerful approach in pharmaceutical sciencej. However, the proteomics has never been demonstrated in the investigation of the multifunctional nanoparticle triggered cellular pathways for cancer therapy. [10] [11] Proteomics facilitated analysis of cellular trafficking induced by nanoparticles would be particularly attractive because it could reveal the mechanic paradigms of the anti-tumor effects from a complex high convergent nanoparticle, consequently, facilitating the development of new drugs for treatment of cancers . We expect that the marriage of SILAC based proteomics and multifunctional nanoparticle would open an unprecedented door for cancer research.
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[43] CODEN (USA): JDDTAO Herein, we present the first example of the cancer therapeutic study for the combinational therapeutics in targeting nanomicelles as drug delivery systems guided by proteomics. The judicious design and synthesis of a multifunctional polymer micelle which incorporates functionalities including membrane estrogen receptor (mER) targeting, mitotic catastrophe inducing, and BcL-2/Bcl-xL inhibiting for mER (+) breast adenocarcinoma is depicted in Figure 1 . In addition to the evaluation of the antitumor effect in vitro and in vivo, the molecular mechanism behind the therapeutic outcome was investigated by systematic epigenetic study and SILAC based proteomes mining. The top molecules and top pathways in the response of the nanoparticle NPG were analyzed. The anti-tumor potency of NPG results from synergistically enhanced mitotic G2/M phase arrest and autophagy instead of the expected apoptosis. The validation of the top gene from the proteomics profiling revealed that the upregulation of ZNF350 is associated with the enhanced antitumor effect of NPG and represents a potential therapeutic target induced by the nanoparticles.
RESULTS AND DISCUSSION
Design, Synthesis and Characterization of the Multifunctional Nanoparticle
The selection of an appropriate ligand for a nanoparticle is critical to ensure its precise and exclusive tumor targeting for the designed nanoparticle based on different types of cancers. To initiate our proteomic directed cancer therapeutic study of multifunctional nanoparticles, mER(+) breast cancer was utilized as a model to test our concept. Thus estrogen was selected as a targeting vector since mERs on the breast cancer cell membrane such as classic ERα, ERα splicing variants (36 kDa, 46 kDa etc.), [12] [13] [14] ER-X, 15 GPR30, and Gαq-mER 16 could bind by estrogens. On the other hand, the dual drugs functioned in different mechanisms such as the anti-mitotic agent paclitaxel (PTX) 17 and a BH3 mimetic gossypol (Gsp) 18 were encapsulated in the nanoparticle. With these key elements synthesized, we fabricate a multifunctional nanodrug delivery system through host-guest recognition between cyclodextrins and adamantyl groups based on our previous established approaches 19 and hydrophobic drug interaction triggered self assembling. 20 In particular, the estrone anchored multifunctional nanomicelles (NPG) consists of five components as shown in Figure 1 and Scheme S1 in Supp Info. They are: anti-mitotic agent paclitaxel (PTX), which was encapsulated in the inner core of NPG; natural BH3 mimetic, a racemic Gsp with low aqueous solubility as adjuvant drug conjugated to the terminal of the di-block polymer to form the hydrophilic G-PEG-PLA; CDE1 as the targeting moiety; adamantane attached polymer AD-PEG-PLA as linker of CDE1 to the nanoparticle; PEG-PLA as the base material in NPG.
The synthetic procedure for the NPG was convergent and straightforward. First, CDE1 was readily synthesized from estrone and amino-β-cyclodextrin 19 through Borch reduction as a targeting moiety. The polymer linker AD-PEG-PLA was prepared by an amidation reaction of the corresponding commercially available admantyl carbonyl chloride and the terminal amine derived PEG-PLA. The drug G-PEG-PLA was installed through the formation of imine functionality from the gossypol and amino-PEG. Through the wellknown host-guest interactions of admantyl group and the cyclodextrin functionality, the conjugate of CDE1 and AD-PEG-PLA was readily formed. After all the components functionalized, the final multifunctional nanoparticle (NPG) was fabricated by a hydrophobic drug-triggered self-assembly and host-guest recognition with overall hydrophilic property. The structure of, the resultant nanoparticle and the corresponding intermediates were fully characterized by nuclear magnet resonance (NMR), mass spectrometry (MS), fourier transform infrared spectroscopy (FTIR) and liquid chromatography (LC) as shown in Figure S1 -3.
To determine the morphology, particle size distribution and surface zeta-potential of the resulting multifunctional NPG, a variety of techniques such as scanning electron microscopy (SEM), transmission electron microscopy (TEM) and dynamic light scattering (DLS) were carried out. The NPG shows a unimodal and narrower size distribution of 18%. The SEM image in Fig 2A showed spherical particles with an average diameter of approximately 170 nm. The size was twice that of the starting material PEG-PLA ( Fig  S7) , indicating the geometrical fabrication of the nanoparticle. TEM microscopic images of NPG displayed an obvious morphology change compared to that of the starting polymer, again indicating the occurrence of the self-aggregation. Additionally, the TEM image clearly showed that the nanoparticle consists of multiple small spherical domains. The small domains were around 170 nm according to the statistical analysis of three samples, supporting that the small domains were conventional micelles self-assembled from the subunits. In addition, the surface charge of the NPG was investigated by DLS, and the results were consistent TEM and SEM, in addition, it showed that the ζ-potential value is 5.8 mV, suggesting thermodynamic and kinetic stability of the nanoparticle. Thus, the asprepared nanoparticles were formed through a selfassembly by host-guest recognition and hydrophilic interactions.
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[44] CODEN (USA): JDDTAO Moreover, the morphology of the nanoparticle in MCF-7 cancer cell was investigated by TEM. TEM images in tissue also showed the structure of the nanoparticle with the diameter of average 170 nm outer shell and inner core with drug encapsulated. Importantly, excellent cell permeability and drug release capability of the multifunctional nanoparticle was observed. As shown in Fig 2F , the TEM image showed that there were quite a few nanoparticles inside the cells, while some of the nanoparticles had been digested and left the out shell alone. Notably, at 15 min after the nanoparticles were internalized into the tumor cells, the typical and delicate two-phase micelle structure with outer hydrophilic layers and inner hydrophobic cores has been clearly observed ( Figure 2F -H), the enlarged one polymeric micelle is shown in Figure 2H , which also demonstrate the successful preparation. The encapsulated drug was released and dispersed inside the MCF-7 cancer cells as shown in Fig 2I. These results demonstrated the promising prerequisite of the resulting multifunctional nanoparticles in treatment of cancer.
Additionally, the NPG demonstrated excellent ratiometric drugs release capability and low cytotoxicity compared to the parent drugs. For instance, the drug release from the nanoparticle significantly lags behind the parent drug, its release was continuous and sustained up to 16.8% for the nanoparticle with kd value of 20.38 vs 83.9% for the encapsulated fluorescent probe with kd =0.4 after 56 h, the drug in the nanoparticle was abruptly dissociated within 0.5 h and then slightly release while the parent drug has a sharp rise at 8 and 24 h with relative drug release percentage of 17.8% and 51.9% respectively ( Figure S5 ). As for the cytotoxic assays, NPG shows a significantly lowered IC50 value (1.9 nM) than the corresponding nontargeting nanopaticle NPC (3.9 nM). Additionally, the progressively declined cytotoxicity response and the long-term drug release of the NPG were more predominant up to 72 h compared with PTX due to the stability of the NPG.
Moreover, the NPG showed the most potent tumor sphere inhibition compared to blank, Gsp, G-PEG-PLA, NPC, and PTX groups as demonstrated in the ex vivo tumor colony inhibition study ( Figure S10 ). For example, when the tumor colonies were exposed to the drugs for 48 h, the tumor colony at the NPG treated group exhibited a 44.0% decrease in size, while only 8.34% in G-PEG-PLA treated group and 18.43% for PTX treated group.
The membrane receptor mediated endocytosis procedure during the internalization of NPG by mER (+) breast cancer cells has been proposed due to the targeting function of CDE1 interpolated in NPG and verified based on the findings. Firstly, TEM was used to capture the process at increasing time periods after exposure to NPG at 50 nM in MCF-7 cells. NPG can only be observed lined up along the cell membrane at the 5 min time point after the treatment with NPG ( Figure 2B , S7), such tight junctions between the nanoparticles and the tumor cell membrane indicates that NPG bonds with plasma membrane protein(s) or certain receptor(s), otherwise the physical association between NPG and cell surface would be disrupted and rinsed off by the following procedure before fixation. The caveolae-like pit with a nanoparticle can be observed on the cell membrane in Figure 2C . During the internalization, the
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newly formed round and small vesicles migrate actively to the cytoplasma membrane for the uptake of the nanoparticles as the arrows show in Figure 2D . At a later time point of 10 min, endosomal vesicles have been observed to disperse and release the nanoparticle drug after internalization as arrows show in Figure 2E . These results provide evidence for the membrane receptor mediated endocytosis for NPG uptake which took place in a quick process. Cristae of mitochondria and other healthy organelles can be observed ( Figure  S7 ) indicating the undamaged cell stage within short drug exposure time. The delicate microstructure of the released drugs and empty polymer shells from the polymer micelles have been captured during the drug release and digestion which give a clear picture for the dynamic process during the internalization, drug release and digestion of NPG by the tumor cells. Secondly, to further confirm the interaction of NPG with mER, flow cytometry analysis was performed in MCF-7 cells. The compound Ada-DOX 19 with intrinsic fluorescence was encapsulated in the estrogen anchored nanoparticles instead of PTX as same equivalent ( Figure S19 ). Figure  S19A shows representative quantitative flow cytometric results of the cellular uptake of the estrogen anchored nanopaticles (T) and non-targeting nanoparticles (N) without estrogen moiety attached. Within 18 h of drug exposure, estrogen anchored nanoparticles uptake by MCF-7 cells has shown a tendency to increase over nontargeting nanoparticles, and considerably augmented uptakes by 11.8% and 34.6% observed at time point of 24 and 48 h compared with non-targeting nanoparticles, which indicates that mER facilitate the uptake of the targeting nanoparticles over the nanoparticle without the estrogen ligands attached. At last, we performed the competition assay with NPG using the synthetic ER ligand analog ethinyl estradiol (EE) and selective ER modulator tamoxifen (TAM) in MCF-7 cells. The results ( Figure S19B ) showed that both EE and TAM at 0.1 and 1 μM inhibited NPG uptake in a concentration independent manner in MCF-7 cells. EE and TAM diminished the uptake of nanoparticles by 25.7% (1M EE), 20.0% (0.1M EE), 14.1% (1M TAM) and 20.7% (0.1M TAM) respectively in MCF-7 cells (***P < 0.001). Based on the findings, the mER mediated endocytosis of NPG internalization has been confirmed.
SILAC Based Proteomic Quantification Analysis
Initial results have shown that the multifunctional NPG exhibited excellent tumor cell growth inhibition, and sustained drugs release through receptor mediated endocytosis. In order to gain comprehensive mechanic information for understanding of cell response triggered by NPG in breast carcinoma cells, a systematic proteomic study of NPG was conducted.
Figure 3
Top canonical pathways (A) and top toxicity pathways (B) enriched in the proteome of multifunctional nanoparticles NPG treated breast cancer cells generated using IPA software. Orange dots indicate ratio, ratio was calculated by dividing the number of genes from our dataset that map to each single pathway by the total number of genes included into the canonical and toxicity pathways. Blue bars denote -log (P-value) by right-tailed Fisher's Exact test, indicating the statistical significance of the molecules in each criterion. Ratio and -log (P-value) are indicated on the left and right side of the histogram, respectively. We Figure 4 .
Figure 4:
Relationships between highest scored regulated pathways trigger by NPG from the SILAC proteomics in MCF-7 cells analyzed by IPA, algorithmically generated based on their functional and biological connectivity, was graphically represented as boxes (pathways) and lines (the biological relationship between the pathways).
The most significant canonic pathways seen are the cell cycle of G2/M, DNA damage checkpoint regulation signaling, PI3K/AKT signaling, Myc mediated apoptosis, mTOR signaling, ERK5 signaling, telomerase extension signaling constitute the majority of pathways highlighted in the drug response induced by NPG. The cell cycle of G2/M DNA damage checkpoint regulation signaling and G1/S checkpoint regulation signaling pathways are indicated to play critical roles for the cytotoxicity in response to the drug NPG. Moreover, in the analysis of upstream regulators, it shows the predicted activation of β-estrodiol relate to the NPG stimulating pathway which reflects the estrogen-like activity of CDE1 ( Figure S11 and Addendum II). In the IPA functional analysis, the protein identifications of top up regulated and down regulated molecules and their fold-change expression with respect to NPG treated MCF-7 breast cancer cells are shown in Table 1 
The interaction of ZNF350 with MMP9, BRCA1 22 and microRNAs are also predicted to be a network based on evidence in literature which is shown in Figure S13 . The proteomics profiling provided valuable information on mechanism and target druggability that will accelerate the downstream drug development, [23] [24] furthermore, allowing us to achieve precise design and implementation for nanomedicines.
Validation of the Cytotoxic Pathways and the Top Regulated Gene in Vitro and in Vivo from Proteomic Annotation
Annotated by the proteomics studies, we further validated the major pathways for the proteomics profiling such as G2/M check point regulation, G1/S check point regulation for cell cycle, apoptosis signaling, PI3k/AKT/mTOR mediated autophagy signaling, and Erk/MAPK signaling annotated in Figure 3 and 4. Firstly, the time course effect of the nano-formulations on cell cycle progression was examined to validatethe key network of NPG response in MCF-7 cells ( Figure 5 and S15-17). Treatment of the MCF-7 cells with NPG at concentrations of 50 nM led to a significant increase in the G2/M population over the 2, 4, 8, 12, 24, 48 and 72 h time periods in comparison to PTX, followed by an increased fraction of the sub-G1 population and appearance of tetraploidy. The G2/M population percentage after NPG treatment for 12 h is 77.6%, 71.03% and 44.80% for NPC and PTX. Increasing the length of drug treatment to 72 h did not further contribute to the G2/M population increase. Overall, NPG caused the most enhanced G2/M accumulation in MCF-7 cells and the effect sustained for the longest observed time period. NPC shows less effect on cell population change of cell cycle than NPG, while more potent than PTX. In regards to Gsp and G-PEG-PLA treated groups, a slight increase for G2/M phase was recorded after 12 h but then change back and became comparable to the control groups for all G1, S, and G2/M phase population. In the investigation of cell cycle associated proteins by time course western blot (WB) for 2 to 72 h drug treatments, the G2/M phase checkpoint regulation though the p53 dependent and p21 WAF1/CIP1 associated CDK1/Cyclin B1 inhibition pathway was shown to be the predominate mechanism to induce tumor cell death induced by NPG. Additionally, MCF-7 cells underwent morphological changes from a polygonal appearance to rounded shape in response to NPG, NPC and PTX treatments at 50 nM for 12 h, NPG and NPC caused more cells damage compared with PTX, while the cells have no obvious morphological difference after the Gsp and G-PEG-PLA treatment at 50 nM for 12 h ( Figure 5D ).
Moreover, mTOR signaling is within the top ten pathways indicated in the proteomics profile about MCF-7 breast cancer cells response after NPG treatment. The time course of NPG preferentially induces mTOR dependent autophagy in MCF-7 cells and in MCF-7 tumor bearing nude mice, was monitored by flow cytometry, WB and confocal microscopy ( Figure 6 and S18). Autophagosome vacuole formation and protein light chain 3 (LC3I/II) upregulation were observed, which have been further proved in animal tumor model by TEM, immunohisto chemistry (IHC) and WB ( Figure S29-31 ). Figure 5 shows flow cytometry analysis of autophagic flux in MCF-7 cells after drug exposure with NPG, Gsp, G-PEG-PLA, NPC and PTX at 50 nM for 12 and 24 h. Notably, NPG induced the formation of autophagic vesicles and autophagosomes more significantly than Gsp, G-PEG-PLA, and NPC compared with the control groups, there is no significant change for parent PTX. Autophagy induced by NPG occurred within hours and was sustained up to 48 h, a longer time period than those witnessed in Gsp, G-PEG-PLA, and NPC. Within the first two hours, there showed 11.8 % autophagic vacuoles and autophagic flux for NPG treated cells compared with 4.1% in Ctrl groups, the groups averaged 11.9, 12.7, 11.2 and 5.5% for Gsp, G-PEG-PLA, NPC, PTX respectively, after drug exposure for 12 and 24 h, at 48 h, most of the cells are in the late stage.
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[48] CODEN (USA): JDDTAO It has been reported that PTX causes inhibition of autophagy in breast cancer cells, both by decreasing autophagosome formation and by altering autophagosome trafficking and localization. 25 Effective autophagy enhancement was observed in MCF-7 cells indicating that NPG stimulates cell death in the appropriate context. NPG induced robust autophagy while paclitaxel released from the micelles blocked a latter step in the pathway and autophagic flux by confocal microscopy. Autophagic vacuole accumulation and flux are both detected by Cyto-ID® Autophagy Green dye as observed after induction with NPG, Gsp, G-PEG-PLA, NPC and PTX for 12 h at 37°C. White arrows indicate the characteristic punctate pattern of autophagosome, which occurs upon autophagic induction.
leading to an accumulation of autophagosomes prior to induction of apoptosis though their effect on autophagy trafficking, resulting in eventual cell death, which suggested that manipulation of autophagy of nanotherapeutics may represent a therapeutic approach for improving breast cancer treatment options. It has been well demonstrated that autophagy depends on Atg5/Atg7, 26 which is associated with microtubule-associated LC3I/II truncation and lipidation, NPG increased LC3 level by 22.9% and 32.2% for LC3I and LC3II separately at 8 h, and 8.1% and 24% at 12 h, and the autophagosome number in MCF-7 cells suggesting that the components in NPG act synergistically to induce autophagy-related cell death in breast cancer cells. Additionally, TEM microimages of MCF-7 cells induced by NPG were captured at early to late stage autophagy. (Figure 7 , S7) The typical autophagic features of cells were observed after treatment with NPG, whereas untreated cells had normal nuclear and cytoplasmic morphology based on the TEM measurement. The initiation, elongation, closure, maturation and degradation stages involved in the autophagy process have been successfully captured separately. The control groups are shown in Figure 7A , without the induction of the drug, the cells are dormant and in an inactive state, clear nuclei and cytoplasma have been observed. The very initial step of autophagy is presented in Figure 7B , the surrounding and sequestering of cytoplasmic organelles and proteins within an isolation membrane, termed phagophore was observed with typical horse-shoe shape (as the red arrow shows). The nascent membranes are fused at their edges to form double-membrane vesicle-autophagosomes (as purple arrows show). Autophagosomes undergo a stepwise maturation process, including docking and fusion with acidified endosomal and/or lysosomal vesicles (as orange arrows show) eventually leading to the delivery of cytoplasmic contents to lysosomal components, where they fuse, then degrade. Furthermore, the time course of upstream regulated proteins associated with autophagy has also been examined ( Figure S18 ). The treatment for NPG caused the down regulation of Akt and phosphorylated PI3K at
[49] CODEN (USA): JDDTAO Tyr199 by 35.6% and 32.2%. Importantly, the downstream-phosphorylated mTOR at Ser248 revealed a 28.2% decrease. Inhibition of the upstream event such as mTOR phosphorylation and PI3k/Akt phosphorylation has been detected along with LC3II generation. Additionally, Beclin-1, also known as the autophagy-related gene, was up-regulated by 19.1% within 8 h in the time course study and reduced by 27.1% subsequently at the 24 h time point, it is most abundant at 24 h for the PTX group. A 29.6% decline in phosphorylated AMPKα at Th172 was also observed.
Moreover, significantly increased expression levels of Erk1 (p42 MAPK) and phosphorylation at Th202 (p-p42 MAPK) have also been recorded which are factors that contribute to autophagy stimulated by NPG. For NPG, G-PEG-PLA, NPC and PTX treated groups, p42 MAPK expression level shows 84.1%, 19.8%, 42.3%, 32.5% increases in comparison to the control groups respectively, and phosphorylated p42 MAPK increases by 111.2%, 221.8%, 249.7%, 222.7% respectively. While Gsp treated groups show comparable amounts of Erk1/2 stimulation to the control groups. In regards to PTEN, there is no significant change observed for all the drug tested groups. The results proved that PI3k/Akt/mTOR and ERK1/2 signaling pathways involved autophagic activity is another major cause of cell death besides mitotic arrest and augments the action of the encapsulated PTX. At the same time, few apoptotic nuclei from the TEM images have been observed unexpectedly. Moreover, according to the detection of the less than 5% apoptotic cell population shown in Figure S20 -S21, it has been concluded that apoptotic activities induced by NPG play a minor role in tumor cell death.
In Vivo Therapeutic Studies in Nude Mice Guide by Proteomics Investigation
Finally, the anti-tumor activity has been evaluated in vivo. Athymic nude mice were implanted subcutaneously with MCF cells. When the animals developed palpable tumors after 10 days, they were treated intravenously with NPG and PTX with equal equivalent (2.36 mg PTX/kg body weight in a total volume of 100 μL) once a week for sequential 5 weeks. Animals in the control group received intravenous administration (i. v.) of saline. In vivo drug distribution within 48 h are shown in Figure 8 in which NPG treated group were injected with the NPG containing 98% PTX and 2% PTX-oregon green 488 conjugate, and PTX treated group using 98% PTX and 2% PTX-oregon green 488 conjugate PTX mixture. Mice in the NPG treated group display dramatically elevated drug uptake in tumor xenograft tissue as compared to Mice of the PTX group which shows nonspecific drug distribution. In addition, the drug excretion though urine was recorded and made detectable through red fluorescence in mice bladders. NPG shows double extended circulation half life time. The first fluorescent urine was recorded at 6 h for the mice in PTX group, while it was at 12 h after the NPG administration. Tumor growth curve, mice body weight change, representative images of gross MCF-7 cell tumors and tumor metastasis detection from dissected organs from the nude mice treated with either control or PTX and NPG respectively are shown in Figure 9 . Mice in the control group developed rapidly growing subcutaneous tumors. After five injections, the average tumor volumes in Ctrl, PTX and NPG treatment groups were 3883.58, 1868.57 and 1084.93 mm 3 respectively. Remarkably, animals in the NPG group exhibited significantly retarded tumor development compared to the animals in the control group (*p<0.05), and shows more potent retarded tumor development than the PTX group.
ISSN: 2250-1177
[51] CODEN (USA): JDDTAO The body weight of the mice in the NPG, PTX and control group shows no significant change. Liver metastasis was detected though bio-fluorescence imaging of the dissected organs from the nude mice injected with GFP transfected MCF-7 tumor cells ( Figure 9D , Figure S24 ). Blue circles indicate the tumor metastasis nodules, and the fluorescence intensity was quantitated by the IVIS spectrum. It revealed that NPG treatment inhibited liver metastasis from breast tumors as well as PTX with the tumor metastasis inhibition rate of 77.83% and 70.71% respectively according to the quantitation of photointensity of the GFP expression site. Notably, NPG markedly alleviated the vein injury traditionally caused by PTX as shown in Figure S25 , The whole blood hematologic and serum biochemical variables were also evaluated for the mice ( Figure S26 ). The complete blood count (CBC) revealed a slightly decreased leukocytes density for the NPG group. Importantly, high platelet counts from the control group, considered to be one indicator of cancer, was ameliorated to normal reference range for 100% of the mice in the NPG treated group, in comparison to 40% of the PTX group. Hematology serum biochemistry parameters show that the serum blood urea nitrogen (BUN) and creatinine level in the control mice was 19.0 mg/dL (20.0-26.0 mg/dL for the normal range) and 0.3 mg/dL (0.5-1.6 mg/dL) in average which is lower than the normal range, the serum BUN and creatinine levels in the NPG treated mice were varied within 20.9 to 24.0 mg/dL which is elevated to the normal range standard reference. There is no remarkable change for the serum levels of alanine amino transferase (ALT) and alkaline phosphatase (ALP) in all of the mice. The H&E stained and the TEM microimages from the tumor sections of the mice treated by the nanoparticles NPG, PTX and saline are shown in Figure S28 and S29, catastrophic cytoplasmic vacuolization has been observed in the tumor tissue of the nanoparticle treated mice more obviously than the other group due to the proposed autophagy caused by NPG.
The proteomics annotation of NPG response in breast cancer cells reveals that the ZNF350 are stimulated during treatment, WB and IHC analysis in vivo confirmed the proteomic data demonstrating that the top gene ZNF350 (or ZBRK1) was significantly more abundant in NPG treated mice than in the control and PTX group (Figure S30,31) . ZNF350 is considered as valuable anti-oncogene for NPG anti-tumor activity in breast cancer. Importantly, activation of ZNF350 is absent in the annotation from the proteomics profiling for all other single constitutes formulated in the nanoparticle as Gsp, polymeric gossypol and PTX. It revealed that ZNF 350 is stimulated uniquely by the integrated drug interaction formulated in the nanoparticles other than the single drug regime. Meanwhile the drug synergism in NPG enhanced the overall therapeutic effect. Therefore our data strengthen the conclusion that ZNF350 may acts as an oncosuppressor in the presence of NPG, revealing ZNF350 to be as a promising therapeutic gene from the antitumor study in vitro and in vivo based on the finding from nanoparticulated drugs. The summary of the validated pathway induced by NPG is shown in Figure  10 . NPG causes comprehensive intracellular signal transduction after the mER facilitated drug internalization and digestion (Supp Info). NPG induces breast tumor cell death though mitotic catastrophe with synergism from PTX, and induces unexpected autophagy resulting from the combinational composites of NPG which is distinct from the single drug actions.
CONCLUSIONS
In summary, we successfully synthesized a novel estrogen anchored multifunctional polymeric nanoparticle NPG for the codelivery of a mitotic agent paclitaxel and a BH3 mimic gossypol which shows advantages over the conventional paclitaxel formulation in vitro and in vivo. The drug mechanism was investigated assisted by systematic SILAC based proteomic study. The NPG treatment in vivo showed improved drug hydrophilicity to avoid the solvent associated side effect of Taxol in clinical use, targeted tumor accumulation, increased drug uptake, extended circulation time in vivo, significant metastasis inhibition, enhanced anti-tumor therapeutic efficacy, protection from vein injury due to intravenous administration, and negligible damage to kidney, liver function as well as immune system at given dosage. Systematic proteomics study and validation in vitro and in vivo for drug response of NPG in breast cancer revealed that synergistically enhanced G2/M phase arrest, PI3K/Akt/mTOR and Erk1/2 mediated autophagy mainly contribute to the mechanism of cancer cell death, instead of the expected inhibition of pro-apoptotic BcL-2 from gossypol besides the mitotic catastrophe resulting from paclitaxel which shows that multifunctional nanoparticles stimulate unique cellular response and results in new mechanisms compared with single drug regimes. NPG is evident as a promising drug 
